Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Allele Traits01:49

Multiple Allele Traits

38.1K
The Concept of Multiple Allelism
38.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

264
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
264
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

311
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
311
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

233
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
233
Multiple Regression01:25

Multiple Regression

4.0K
Multiple regression assesses a linear relationship between one response or dependent variable and two or more independent variables. It has many practical applications.
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
4.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

301
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status.

Multiple sclerosis and related disorders·2026
Same author

Factors Influencing Early and Late B-Cell Repopulation After Rituximab Therapy in Pediatric Central Nervous System Inflammatory Disorders.

Pediatric neurology·2026
Same author

Higher ultra-processed food consumption is associated with higher likelihood of paediatric-onset multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis Prognosis.

Neurology and therapy·2026
Same author

Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS.

Acta neuropathologica·2026
Same author

Paediatric cerebrospinal fluid immune profiling distinguishes paediatric-onset multiple sclerosis from other paediatric-onset acute neurological disorders.

EBioMedicine·2026
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K

Pediatric Multiple Sclerosis: an Update.

Scott Otallah1, Brenda Banwell2,3

  • 1Pediatric Multiple Sclerosis and Demyelinating Disorders Clinic, Division of Pediatric Neurology, Department of Neurology, Wake Forest University/Brenner Children's Hospital, Medical Center Boulevard, JT9, Winston Salem, NC, 27157, USA. sotallah@wakehealth.edu.

Current Neurology and Neuroscience Reports
|September 20, 2018
PubMed
Summary
This summary is machine-generated.

Recent advancements in pediatric-onset multiple sclerosis (POMS) include updated diagnostic criteria and insights into disease impact. Research now better defines POMS, guiding improved care for affected children.

Keywords:
2017 McDonald CriteriaFingolimodMOGMyelin oligodendrocyte glycoprotein antibodyPediatric multiple sclerosisReview

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K

Related Experiment Videos

Last Updated: Feb 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.8K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K

Area of Science:

  • Pediatric Neurology
  • Demyelinating Diseases
  • Neuroimmunology

Background:

  • Pediatric-onset multiple sclerosis (POMS) and related demyelinating disorders require updated diagnostic and management strategies.
  • Advances in neuroimaging, biological assays, and clinical trials are transforming the understanding and treatment of these conditions in children.

Purpose of the Study:

  • To provide healthcare providers with current updates on POMS and related demyelinating disorders.
  • To summarize recent findings in diagnosis, neuroimaging, biomarkers, treatment, and outcomes for pediatric MS.

Main Methods:

  • Review of updated diagnostic criteria (2017 McDonald Criteria) for applicability to POMS.
  • Analysis of neuroimaging studies revealing brain volume changes and tissue integrity.
  • Examination of biological assays for antibodies (e.g., MOG antibodies) and their diagnostic/prognostic significance.
  • Evaluation of data from clinical trials on treatment efficacy and safety (e.g., fingolimod vs. interferon beta 1a).
  • Assessment of longitudinal studies on neurological, cognitive, and quality of life outcomes.

Main Results:

  • The 2017 McDonald Criteria are applicable to POMS, simplifying diagnosis.
  • Neuroimaging shows reduced brain volume at onset and progressive decline, similar to adult MS.
  • Myelin oligodendrocyte glycoprotein (MOG) antibodies are present in over 50% of acute disseminated encephalomyelitis cases in children and can indicate relapsing disease.
  • Fingolimod demonstrated superiority over subcutaneous interferon beta 1a with a favorable safety profile in clinical trials.
  • Despite low Expanded Disability Status Scale scores early on, POMS is linked to fatigue, reduced exercise, and cognitive impairment risks.

Conclusions:

  • Significant progress has been made in recognizing and researching POMS over the last 15 years.
  • More specific diagnostic criteria and antibody biomarkers are defining distinct disorders.
  • Clinical trials are yielding evidence for effective and safe treatments.
  • A deeper understanding of POMS' impact on children's neurological function, cognition, and quality of life is emerging.